Full text is available at the source.
Abstract
Among 13,725 GLP-1RA-treated adults, carriers of rare damaging GLP1R variants lose less weight with semaglutide but achieve a near-normal response with tirzepatide.
- Carriers of rare GLP1R variants exhibit reduced weight loss when treated with semaglutide compared to matched non-carriers.
- Tirzepatide treatment results in near-normal weight loss responses for individuals with rare GLP1R variants.
- Normal weight loss responses are observed in carriers of rare GIPR variants, which target the glucose-dependent insulinotropic polypeptide receptor.
- The findings indicate that rare genetic variants may influence the efficacy of specific GLP-1 receptor agonists.
Simplified